| Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin - Liver International |
| Asselah T et al. – The future of HCV treatment would probably consist in the addition of specifically targeted antiviral therapy for HCV such as protease and/or polymerase inhibitors to the SOC. In genotype 1 patients, very promising results have been reported when the protease inhibitor telaprevir or boceprevir is added to the SOC. It increases the SVR rates from approximately 50% (PEG–IFN plus ribavirin) to 70% (for patients treated with a combination of PEG–IFN plus ribavirin plus telaprevir).... |
| Pharmacological Therapies for Osteoarthritis of the Hand: A Review of the Evidence - Drugs & Aging |
| Altman RD – Pharmacological approaches have included several oral therapies, such as paracetamol (acetaminophen), oral nonsteroidal anti–inflammatory drugs (NSAIDs) and opioids, all of which carry a risk of adverse events that typically increases with age. Topical NSAIDs, recently approved in the US, appear to provide efficacy similar to that of oral NSAIDs for hand OA, with less systemic NSAID exposure. Intra–articular corticosteroids and hyaluronic acid have also shown modest symptomatic efficacy with generally good tolerability. Two proposed disease–modifying therapies, chondroitin sulfate and hydroxychloroquine, have had unclear effects on disease modification in clinical trials. This review of pharmacotherapies for the treatment of hand OA focuses on their efficacy and safety in elderly patients.... |
| The addition of pioglitazone in type 2 diabetics poorly controlled on insulin therapy: A meta-analysis - European Journal of Internal Medicine |
| Tan A et al. – This study implied that in patients with type 2 DM whose control is inadequate on insulin therapy, the additional pioglitazone could significantly improve glucose metabolism and might have a positive effect on important components of the lipid profile, which may have important implications in reducing the risk of cardiovascular disease, a major long–term complication in type 2 diabetes mellitus. Besides, the adverse events were well tolerated.... |
Previous Page...
More News...
|